Illumina, Inc. (ILMN)

NASDAQ: ILMN · IEX Real-Time Price · USD
+8.19 (3.83%)
At close: Mar 29, 2023, 4:00 PM
+0.47 (0.21%)
Pre-market: Mar 30, 2023, 7:09 AM EDT
Market Cap 35.08B
Revenue (ttm) 4.58B
Net Income (ttm) -4.40B
Shares Out 158.00M
EPS (ttm) -28.00
PE Ratio n/a
Forward PE 72.99
Dividend n/a
Ex-Dividend Date n/a
Volume 1,084,197
Open 222.12
Previous Close 213.84
Day's Range 219.34 - 227.61
52-Week Range 173.45 - 371.16
Beta 1.15
Analysts Buy
Price Target 239.88 (+8.04%)
Earnings Date May 3, 2023

About ILMN

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as canc... [Read more]

Sector Healthcare
IPO Date Jul 28, 2000
Employees 9,800
Stock Exchange NASDAQ
Ticker Symbol ILMN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 25 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price forecast is $239.88, which is an increase of 8.04% from the latest price.

Price Target
(8.04% upside)
Analyst Consensus: Buy
Stock Forecasts


Illumina (ILMN) to Enable Tertiary Analysis With New Launch

Illumina's (ILMN) Connected Software is an end-to-end software system that standardizes analysis tools and connects data across the genomics workflow.

18 hours ago - Zacks Investment Research

Carl Icahn wants to bring back Illumina's ex-CEO 'immediately' as proxy fight intensifies

Icahn said Illumina should bring back former CEO Jay Flatley, saying current management is making the mistake of holding onto the $7.1 billion Grail deal.

Other symbols: IEP
21 hours ago - CNBC

Carl Icahn tells WSJ he wants old CEO back at Illumina

Illumina Inc. ILMN activist shareholder and billionaire Carl Icahn told The Wall Street Journal he'd like to see the return of ex-CEO Jay Flatley to replace the gene sequencing device maker's current ...

23 hours ago - Market Watch

DNA Data Storage Alliance Announces Board Appointments

SAN DIEGO--(BUSINESS WIRE)--The DNA Data Storage Alliance, a SNIA Technology Affiliate, formed in 2020 by Illumina, Inc. (NASDAQ: ILMN), Microsoft (Nasdaq: MSFT), Twist Bioscience Corporation (NASDAQ:...

Other symbols: MSFTTWSTWDC
1 day ago - Business Wire

Carl Icahn Wants to Bring Illumina's Old CEO Back

The billionaire activist, who has launched a proxy battle at Illumina, wants change at the management level too, and he has a candidate in mind for the top spot: former CEO Jay Flatley.

1 day ago - WSJ

Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease

As demand for clinical next-generation sequencing grows, Illumina Connected Insights enables user to streamline data interpretation and report generation to inform precision care SAN DIEGO , March 27,...

2 days ago - PRNewsWire

Illumina Issues Statement in Response to Carl Icahn's Letter

SAN DIEGO , March 24, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, issued the following statement in response to a letter from Ca...

5 days ago - PRNewsWire

Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal

Carl Icahn claims Illumina directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of Grail

5 days ago - CNBC

Biotech company Illumina pushes back against Carl Icahn's proxy fight over $7.1 billion Grail deal

Illumina pushed back against Carl Icahn's proxy fight over the Grail deal, saying it's committed to maximizing shareholder value as it works with regulators.

1 week ago - CNBC

Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's Statements

Illumina's plan will maximize shareholder value Illumina is engaged with regulators to define GRAIL's path forward as expeditiously as possible Icahn's director nominees do not add value to the Board ...

1 week ago - PRNewsWire

3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time

Healthcare costs in America and the world are set to rise in the foreseeable future. All thanks to an aging population, and the expectation that healthcare companies will be able to cure more of our d...

Other symbols: ARAYCRSP
1 week ago - InvestorPlace

Icahn proposes three candidates for Illumina's board — Here's what could be next in the battle

A fight has broken out between veteran activist Carl Icahn and biotech company Illumina as the investor nominates three candidates to the board.

1 week ago - CNBC

Illumina Should Heed Icahn, Give Up on Holy Grail

Management should seek a settlement with the activist that paves the way for a speedier Grail exit

1 week ago - WSJ

Carl Icahn Responds to Illumina in Open Letter

Sunny Isles Beach, Florida, March 15, 2023 — Today, Carl C. Icahn released the following open letter to the shareholders of Illumina, Inc. ( ILMN , Financial), responding to the obfuscations contained...

1 week ago - GuruFocus

Illumina (ILMN) Unveils Complete Long Reads Technology

Illumina's (ILMN) Complete Long Read Prep combines Illumina sequencing by synthesis chemistry with DRAGEN secondary analysis to provide WGS with more accuracy.

2 weeks ago - Zacks Investment Research

Illumina launches its first product enabling long- and short-read sequencing on one instrument

Early customer data reinforces accuracy and flexibility of novel long-read technology, unlocking access to challenging, low DNA input samples SAN DIEGO , March 14, 2023 /PRNewswire/ -- Illumina Inc. (...

2 weeks ago - PRNewsWire

Carl Icahn Pens Open Letter to Illumina Shareholders

Sunny Isles Beach, Florida, March 13, 2023 — Today, Carl C. Icahn released the following open letter to the shareholders of Illumina, Inc. ( ILMN , Financial).

2 weeks ago - GuruFocus

Illumina: It's not in the ‘best interests' of shareholders to support Carl Icahn's nominees to the board

Illumina Inc. ILMN said Monday it received notice from Icahn Partners that the organization plans to nominate three candidates to to the board over concerns about the company's $7.1 billion acquisitio...

2 weeks ago - Market Watch

Illumina Responds to Icahn Partners' Nomination of Directors

SAN DIEGO , March 13, 2023 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, confirmed today that it has received notice from Icahn Partner...

2 weeks ago - PRNewsWire

ILMN Stock Alert: What to Know as Carl Icahn Prepares for Proxy Fight With Illumina

Illumina (NASDAQ: ILMN) stock is a hot topic among traders on Monday as reports claim Carl Icahn is gearing up for a proxy fight. According to a report from The Wall Street Journal, Icahn has issues ...

2 weeks ago - InvestorPlace

WSJ: Carl Icahn says Grail deal cost Illumina shareholders $50 billion

Shares of Illumina Inc. ILMN, -4.24% were up about 8% in premarket trading on Monday after the Wall Street Journal reported Sunday that Carl Icahn is planning a proxy fight. The billionaire activist r...

2 weeks ago - Market Watch

Carl Icahn Is Taking Aim at Illumina

Carl Icahn plans to nominate three people to Illumina's board, according to The Wall Street Journal.

2 weeks ago - Barrons

Carl Icahn prepares for proxy fight at Illumina - WSJ

Activist investor Carl Icahn is preparing a proxy fight at Illumina Inc , arguing that the life science maker's acquisition of Grail Inc cost its shareholders roughly $50 billion, the Wall Street Jour...

2 weeks ago - Reuters

Icahn Prepares for Proxy Fight at Illumina

The billionaire activist seeks three seats on biotech's board.

2 weeks ago - WSJ

Steer Clear Of These 4 Toxic Stocks to Avoid Losses

Correctly spotting overpriced stocks and shunning them at the right time may avoid portfolio bleeding. ILMN, LTRX, BSY and CDMO are a few such toxic stocks.

Other symbols: BSYCDMOLTRX
2 weeks ago - Zacks Investment Research